Welcome to our dedicated page for FOXO TECHNOLOGIES news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO TECHNOLOGIES stock.
FOXO Technologies Inc. operates healthcare-related subsidiaries that include a critical access acute care hospital, a behavioral health treatment business, a biotechnology subsidiary and Vector BioSource, a biospecimen and data sourcing provider for biotechnology, clinical research and pharmaceutical research customers.
Company news commonly covers clinical-capability additions at Big South Fork Medical Center, swing-bed and specialty-care arrangements, license and operating updates for Myrtle Recovery Centers, acquisition activity, capital-structure actions and trading-status developments for FOXO common stock on the OTC market.
FOXO Technologies Inc. (AMEX: FOXO) announced the resignation of Chief Product Officer Erin Sharoni effective November 9, 2022. The company expressed gratitude for her leadership, particularly regarding the FOXO Longevity Report. FOXO Technologies focuses on applying epigenetic science and AI to modernize the life insurance sector through innovative products and services aimed at improving underwriting processes and consumer value.
FOXO Technologies Inc. (AMEX: FOXO) has announced the postponement of its earnings conference call, with a subsequent press release to reveal the new date and time. This delay could indicate potential issues or uncertainty regarding the company's financial performance and outlook. FOXO operates at the intersection of technology and life insurance, focusing on epigenetic longevity science aimed at improving consumer underwriting processes through innovations like the FOXO Longevity Report™.
FOXO Technologies has announced a new managing general agency agreement between its subsidiary, FOXO LIFE, and Haven Life, a subsidiary of MassMutual. This strategic partnership aims to enhance FOXO LIFE's distribution of Haven Life insurance products through independent agents. This collaboration is set to expand FOXO LIFE's market reach, leveraging Haven Life's innovative digital purchasing experience in the life insurance sector. The announcement comes ahead of the NAILBA Annual Meeting, emphasizing FOXO's commitment to modernizing life insurance through technology.
FOXO Technologies Inc. (FOXO) announced it will report its financial results for the third quarter of 2022 on November 14, 2022, after market close. A conference call will be held at 3:15 p.m. Central time on the same day to discuss the results and recent business highlights. FOXO is focused on leveraging epigenetic technology to modernize the life insurance industry, utilizing AI to analyze DNA methylation for health biomarkers, enhancing the underwriting process, and improving consumer value prop through its FOXO Longevity Report.
FOXO Technologies Inc. (AMEX: FOXO) announced the recruitment of its first distribution partner, BGA Insurance, which represents over 4,000 independent agents in California. This partnership aims to promote longevity-focused life insurance products through FOXO LIFE. Additionally, James Grauel, Jr. has been appointed as Chief Distribution Officer to lead these efforts. The company will conduct agent recruitment events in Southern California starting October 19, 2022. The announcement follows FOXO's recent public trading debut with an enterprise value of approximately $369 million.
FOXO Technologies Inc. announced the completion of its business combination with Delwinds Insurance Acquisition Corp., with trading starting on the NYSE American under the symbol 'FOXO' from September 16, 2022. This strategic move aims to address key issues within the life insurance sector through epigenetic longevity science. FOXO's inaugural Managing General Agency relationship allows for marketing a range of life insurance products bundled with the FOXO Longevity Report™. The business combination received over 91% shareholder approval, underscoring strong investor confidence.